Wolverine Trading’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Wolverine Trading’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-12,500	Closed	-$54K	–	5255
2023 Q1	$54K	Buy	+12,500	New	+$64.9K	﹤0.01%	3821
2022 Q4	–	Sell	-11,800	Closed	-$66K	–	5484
2022 Q3	$66K	Buy	+11,800	New	+$73.5K	﹤0.01%	4065
2022 Q2	–	Sell	-53,500	Closed	-$268K	–	6262
2022 Q1	$268K	Buy	53,500 +42,000	+365%	+$125K	﹤0.01%	4054
2021 Q4	$29K	Sell	11,500 -10,600	-48%	-$25.9K	﹤0.01%	5460
2021 Q3	$65K	Buy	22,100 +2,000	+10%	+$5.45K	﹤0.01%	5957
2021 Q2	$50K	Sell	20,100 -600	-3%	-$1.44K	﹤0.01%	5604
2021 Q1	$55K	Buy	+20,700	New	+$67.6K	﹤0.01%	5630
2019 Q3	–	Sell	-13,600	Closed	-$12K	–	5406
2019 Q2	$12K	Buy	13,600 +1,100	+9%	+$1.01K	﹤0.01%	4306
2019 Q1	$12K	Buy	+12,500	New	+$13.2K	﹤0.01%	4424
2018 Q3	–	Sell	-15,300	Closed	-$60K	–	6523
2018 Q2	$60K	Hold	15,300	–	–	﹤0.01%	4866
2018 Q1	$60K	Buy	+15,300	New	+$53.8K	﹤0.01%	4866

Other funds holding CTIC

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Wolverine Trading's CTIC Position: Q2 2023 in Review

Wolverine Trading sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 15,764 shares — an estimated $67K sold.

Wolverine Trading first reported a position in CTIC in Q1 2018 and held it in 8 quarters. The position peaked at $236K in Q1 2022. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.

Wolverine Trading reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
Wolverine Trading sold 15,764 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $67K.
Wolverine Trading first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q1 2018 and held it in 8 quarters.
Wolverine Trading's CTI BioPharma Corp. (DE) Common Stock position peaked at $236K in Q1 2022.
2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.

Based on Wolverine Trading's 13F filing for Q2 2023, filed 23 Aug 2023.